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Acquisition of immortalization by somatic cells is 
one of the hallmarks of tumorigenesis [1, 2]. Immor-
talization is a complex process, which involves not only 
activation of telomerase (TERT), but also changes in 
a number of signalling mechanisms related to regula-
tion of cell proliferation and apoptosis [3–5]. Among 
such cell cycle regulators are cyclin-dependent kinase 
inhibitor p16INK4a, p53, MAP kinase and pRb (reviewed 
in [3–5]). Further studies are expected to unveil the 
whole complexity of immortalization, and to describe 
all involved proteins and genes.
Kinase Suppressor of Ras 2 (KSR2) is a scaffold pro-
tein involved in activation of MAP kinase pathway [6, 7]. 
KSR2 was found to mediate A-Raf signalling. However, 
a screening for KSR2 interacting proteins showed that 
KSR2 may play a broader role in regulation of cell pro-
liferation, by forming high-order complex(es) including 
kinases (MEK1, MEK2, Erk2, p38, cdk4, PI3K) and 
phosphatases (PP2A, PP6), translational, ribosomal, 
transport and structural proteins [8]. These findings 
indicated that KSR2 may play a role in tumorigenesis.
A model of immortalization of human breast epi-
thelial cells was recently developed using conditional 
immortalization of primary cells [9]. Temperature-
sensitive construct of SV40 LT in combination with 
hTERT allowed controlled immortalization of human 
primary cells [9]. This model of immortalization was 
found suitable for studies of signalling mechanisms 
of the transition from immortalization to senescence. 
Proteome profiling of these cells showed that im-
mortalization-to-senescence transition leads to the 
changes in expression of a number of proteins [10]. 
Some of them, like KSR2, could be directly involved 
in regulation of cell proliferation.
MATERIAL AND METHODS
Cells. 184A1 and MCF10A cells were obtained from 
ATCC (Manassas, USA), and were cultured in media 
recommended by ATCC. Conditionally immortalized 
human primary epithelial cells were generated using 
constructs and methods described early by O´Hare et 
al. [9]. Notably, the catalytic subunit of human telom-
erase (hTERT) and a temperature-sensitive mutant 
of simian virus 40 large-tumor antigen were used 
(non-DNA binding non-Bub1 binding thermolabile T 
antigen; [9]). The luminal 226Lts4 and 226LU19 cells 
were used. Expression of LT antigen was confirmed by 
immunoblotting, and hTERT was monitored by TRAP 
assay (O’Hare and Jat; manuscript).
Proteomics. Proteome profiling of conditionally 
immortalized cells, two-dimensional gel electropho-
resis, gel image analysis and MALDI TOF mass spec-
trometry for identification of differentially expressed 
proteins were described by Jia et al. [10].
Network analysis of KSR2 for interactors. 
FunCoup tool was used to identify KSR2 interactors 
(http://funcoup.sbc.su.se). FunCoup operates with 
databases which have been selected for their thorough 
analysis and incorporation of experimental data. This 
ensures that only confirmed by multiple laboratories 
results are taken into consideration for building a net-
work. Settings for the network analysis were as follows: 
confidence score 0.10, only direct one-step interactors 
observed in humans were considered.
Transfections and immunoblotting. Cells were 
transfected in 6-wells plates by LipofectAMINE 2000 re-
agent, as recommended by the supplier (Invitrogen, 
Carlsbad, USA). pcDNA3-KSR2 construct was kindly 
provided by Dr. Jiahuai Han. siRNA to KSR2 (ID # 41069) 
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was obtained from Ambion (Austin, USA). Control scram-
bled siRNA (sc-37007) were obtained from SantaCruz 
Biotech (Santa Cruz, USA). Media was changed 6 hs 
after transfection. For immunoblotting, cell lysates were 
resolved on SDS polyacrylamide gels and transferred 
onto Hybond P membranes (GE Healthcare, Piscataway, 
NJ). Membranes were blocked with 5% (v/v) BSA and 
then incubated with a primary antibody against KSR2 
(H00283455-A01; Abnova, Taiwan) as recommended by 
manufacturer, and followed by an HRP-conjugated sec-
ondary antibody (GE Healthcare, Uppsala, Sweden). The 
proteins were visualized using Western Blotting Luminol 
Reagents (Santa Cruz Biotechnology Inc.). For transfec-
tion with siRNA, cells were seeded in 24-well plates, and 
transfection procedure was performed the next day, as 
recommended by the siRNA suppliers. After transfection, 
cells were cultured in a medium supplemented with 10% 
FBS before assays.
Cell proliferation assays. Cell proliferation was 
measured using [3H]thymidine incorporation assay and 
CellTiter 96® Non-Radioactive Cell Proliferation Assay 
(MTT assay) (Promega, Promega Biotech AB, Stock-
holm, Sweden). 184A1 and MCF10A cells were seeded 
in plates for proliferation assays. Cells were incubated 
with 0.1 Ci/ml of [3H]thymidine for the last 24 hs of the 
72 hs incubation time period. Radioactivity incorporated 
in DNA was measured as described earlier [11]. MTT 
assay was performed in parallel with [3H]thymidine-
incorporation test, except that no radioactivity was 
added. Cells were grown for the 72 hours, and MTT 
assay was performed according to the manufacturer’s 
recommendations. Statistical significance of observed 
differences was evaluated using Student’s t-test.
Immunohistochemistry. AccuMax breast cancer 
arrays (ISU ABXIS Co., Ltd, Seoul, South Korea) were 
used. Each array slide contains 45 cases of cancer 
tissues and 4 non-neoplastic tissues. Arrays were 
stained with anti-KSR2 antibody (H00283455-A01; 
Abnova) at a dilution of 1:250. Antigen retrieval was 
performed using DakoCytomation target retrieval solu-
tion high pH (DAKO, Carpinteria, CA, USA). The slides 
were stained with VECTASTAIN Elite ABC kits (Vector 
Laboratories Inc., Burlingame, CA, USA) following 
the manufacturer’s instruction, counterstained with 
hematoxylin and mounted with Fluoromount G (Sou-
thern Biotechnology, Birmingham, AL). The stained 
tissues were photographed using a Leica DFC camera 
and images were acquired with Leica QWin Standard 
software (Leica Microsystems Imaging Solutions Ltd, 
Cambridge, UK). Intensity of staining was evaluated as 
absent ((-), no staining or weak staining in fewer than 
5% of cells) middle/present ((+), staining in > 5% but 
< 50% of cells), and strong ((++), staining in > 50% 
of cells). Staining was evaluated in tumor cells and 
epithelial cells of normal tissues.
RESULTS AND DISCUSSION
Using proteomics approach KSR2 was identified 
as an up-regulated protein in immortal human primary 
epithelial cells [10]. Protein spot containing KSR2 was 
detected only in immortal cells, which indicated 
up-regulation of at least more than 2 fold (Fig. 1). 
Conditionally immortalized cells were generated by 
expression of hTERT and temperature-sensitive mu-
tant (U19tsA58) of simian virus 40 large-tumor (LT) 
antigen, as described by O´Hare et al. [9].
Non-immortal Immortal
KSR2
Fig. 1. Images of inserts of 2D gels which show the protein 
spots of KSR2. Images show the KSR2 spot in 2D gels from 
cells cultured under permissive (Immortal) and non-permissive 
(Non-immortal) conditions. Arrows indicate migration position 
of the protein spot of KSR2.
KSR2 is a scaffold protein in mitogen-activated 
protein kinase (MAPK) pathways [6–8]. To explore 
potential impact of KSR2 on cell proliferation and 
generic MAPK pathways in unbiased way, we used 
FunCoup tool (http://funcoup.sbc.su.se). The gene-
rated network (Fig. 2) showed potential involvement of 
Raf-1, mitogen-activated kinases 1 and 3 (MAPK1 and 
MAPK3), mitogen-activated kinase kinase 1 (MAP2K1) 
and MAPK scaffold protein 1 (MAPKSP1) (Fig. 2). 
These molecules provide further links to regulators of 
the cell cycle, p53 and hTERT (data not shown). A num-
ber of other KSR2 interactors involved in regulation 
of the cell cycle were reported, although they have to 
be validated [8]. Thus, analysis of the KSR2-centered 
network indicated that KSR2 may have an impact on 
cell proliferation.
KSR2
MAPKSP1 MAPK3
MAPK1
RAF1
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Fig. 2. KSR2 forms a network with components of Raf/MAP ki-
nase signalling. The network of interacting proteins was built with 
KSR2 as a hub, using FunCoup tool (http://funcoup.sbc.su.se).
To manipulate KSR2 level in cells subjected to 
cell proliferation assays, we enhanced expression of 
KSR2 by transfecting cells with a specific vector or 
down-regulated KSR2 with a specific siRNA (Fig. 3). 
We studied two human breast epithelial cell lines, 
MCF10A and 184A1, which are both non-tumorigenic 
and considered to have normal phenotype of human 
breast epithelial cells. These cells can be cultured 
in vitro, and therefore are immortalized. Both cell lines 
also express KSR2 (Fig. 3). However, 184A1 cells may 
undergo immortalization crisis, and have lower prolif-
eration potential, as compared to MCF10A cells [12].
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Fig. 3. Down-regulation of KSR2 resulted in inhibition of the cell 
proliferation. (a) 184A1 and MCF10A cells were transfected with 
siRNA to KSR2, and with control siRNAs, as indicated. Prolifera-
tion of cells was monitored by measurement of [3H]thymidine 
incorporation. (b) 184A1 and MCF10A cells were transfected with 
KSR2 expressing vector, and with control empty pcDNA3 vec-
tor, as indicated. Cell proliferation was measured by MTT assay. 
Expression of KSR2 (a,b) was monitored by immunobloting of 
the whole cell extracts. Migration position of a 47.5 kDa marker 
is indicated on the side of gel panel. Statistical significance in 
assays was calculated by Student’s t-test.
We observed that down-regulation of KSR2 had a 
strong inhibitory effect on proliferation of both cell lines 
(Fig. 3a). KSR2 overexpression had rather weak ef-
fect on cell proliferation, which was more pronounced 
for 184A1 cells, but not significant for MCF10A cells 
(Fig. 3b). This could be explained by the presence of 
endogenous KSR2 in a quantity already sufficient for 
its normal functions. On the other hand, decrease in 
KSR2 expression by siRNA, had an inhibitory impact 
on proliferation of both cell lines, indicating the rate-
limiting role of KSR2. Thus, KSR2 is involved in main-
taining the cell proliferation rate.
To explore whether KSR2 expression could be 
altered in breast tumors, we performed immunohisto-
chemistry study of human breast tissue microarray. The 
microarray consisted of 29 cases of infiltrating ductal 
carcinomas (IDC), 8 papillary carcinomas, 4 cases of 
infiltrating lobular carcinomas (ILC) and 4 normal breast 
tissues. We observed an increase of KSR2 staining in 
epithelial cells of IDC tumors, as compared with normal 
breast tissue (Fig. 4a, b). We observed KSR2 staining 
in all 29 cases of IDC, 4 cases of ILC and 8 cases of 
papillary carcinomas (Fig. 4c). All samples of normal 
breast tissue did not show KSR2 staining. KSR2 stain-
ing in tumor samples was detected mainly in cytoplasm 
of cells. No correlations of KSR2 expression with TNM 
gradation of tumors were observed.
a
b
×200
×400
×200
×400
Samples Staining(-) (+) (++)
Invasive Ductal Carcinoma (29 cases) 0 10 19
Invasive Lobular Carcinoma (4 cases) 0 2 2
Papillary Carcinoma (8 cases) 0 6 2
Normal (4 cases) 4 0 0
Fig. 4. Expression of KSR2 was increased in human infiltrating ductal 
carcinomas. Representative images of immunohistochemistry stain-
ings for KSR2 are shown: (a) staining of normal human breast tissue; 
(b) staining of an infiltrating ductal carcinoma case. Magnifications are 
X200 (top images in panels) and X400 (lower images in panels). (c) 
Quantification of KSR2 staining in human breast cancer. Evaluation 
of staining was performed as described in the material and methods 
section. Numbers indicate numbers of cases with corresponding 
detection of staining (as (-), (+) and (++)), and the total number of 
cases is mentioned in the left column.
212 Experimental Oncology 32, 209–212, 2010 (September)
KSR2 plays an important role in activation of vari-
ous signalling events, with reported role in signalling by 
p38 MAPK and MAP2K3 [6–8]. We found that KSR2 is 
involved in regulation of cell proliferation, and is up-
regulated in tumor epithelial cells in human invasive duc-
tal, invasive lobular and papillary carcinomas of breast. 
In conclusion, our findings provide evidence of a potential 
role of KSR2 in tumorigenesis, indicating that expression 
of KSR2 may be changed already upon acquisition by 
cells the ability to non-limited proliferation.
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